Past Causes

Who We Have Supported

Since its inception, ReMission Foundation has been fortunate to collaborate with many important organizations and researchers focused on cancer research, prevention, and improving quality of life for those impacted by cancer. You can find more information about past causes below.

2018

Yelena Y. Janjigian MD, Medical Oncologist at Memorial Sloan Kettering Cancer Center and her esophagogastric (esophagus and stomach) cancer research.

ReMission Foundation, with the support of Memorial Sloan Kettering Cancer Center, is pleased to support Yelena Y. Janjigian MD, Medical Oncologist at Memorial Sloan Kettering Cancer Center and her esophagogastric (esophagus and stomach) cancer research. Dr. Yelena Y. Janjigian is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in the treatment of malignancies of the gastrointestinal tract, including esophagus and stomach cancers. Her research focuses on development of new treatments for patients with esophagus and stomach cancers. Dr. Janjigian has special interest in finding the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens.

Currently, Dr. Janjigian and her fellow investigators are conducting game-changing research to determine why esophagogastric cancers become resistant to treatment and to develop new laboratory approaches to study this devastating disease. In support of Dr. Janjigian efforts, ReMission Foundation is supporting specfic clinical trials focused on immunotherapy for gastric cancer patients. Rather than targeting a tumor with chemotherapy and radiation, immunotherapy harnesses the immune system, and empowers it to seek out and destroy cancer cells. One of the most promising forms of immunotherapy is checkpoint inhibitors—these drugs release the breaks on the immune systems, which, in turn, stimulates a patient’s T cells to attack and kill cancer.

Dr. Janjigian strongly believes this combined approach will save lives, and eventually, change the landscape of cancer care as we know it. This trial is also one of the first studies designed to prove the efficacy of ctDNA and move the needle on how it can be used. Funding is critical to move forward with this proposed study.

Dr. Janjigian anticipates this trial will cost $1.2 million. She has secured $400,000 in funding thus far and ReMission Foundation is helping raise funds to support her efforts. To learn more about Dr. Janjigian and her work in esophagogastric cancer prevention, please visit Yelena Y. Janjigian


2017

Peter S. Liang MD, MPH, Instructor at the NYU School of Medicine and an attending physician at the VA New York Harbor Healthcare System

ReMission Foundation, with the support of the Division of Gastroenterology, Department of Medicine at NYU Langone Medical Center led by Mark B. Pochapin MD, is proud to support Peter S. Liang MD, MPH, Instructor at the NYU School of Medicine and an attending physician at the VA New York Harbor Healthcare System and his colorectal cancer prevention research. Dr. Liang studies sociodemographic and geographic disparities in colorectal cancer screening and outcomes, the comparative effectiveness of different screening strategies, and novel methods to increase screening adherence. He also maintains interests in gastric cancer prevention and the management of upper gastrointestinal bleeding.

Dr. Liang is currently planning two database studies of patients who have received care at NYU Langone Medical Center and Bellevue Hospital Center:

  • Risk factors for early onset colorectal cancer
  • Predictors of colorectal cancer screening at Bellevue Hospital Center

  • The results of these studies will allow us to focus our efforts to increase screening in these communities.

    About Peter S. Liang, MD
    Dr. Liang completed his undergraduate degrees in Biological Sciences and East Asian Studies with honors and distinction at Stanford University and was a Fulbright Fellow in China. He attended Harvard Medical School and earned a master’s in public health in Quantitative Methods at the Harvard School of Public Health. He completed his internal medicine residency at Brigham and Women’s Hospital and his gastroenterology fellowship at the University of Washington. Dr. Liang is actively involved in several national societies, including the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the National Colorectal Cancer Round Table. You can learn more about Dr. Liang and his work in colorectal cancer prevention by visiting the following website


    2016

    Breast Cancer Alliance

    ReMission Foundation is proud to support Breast Cancer Alliance (BCA) in support of their efforts to fight breast cancer. BCA’s mission is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, BCA funds innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved. Over its 20 years, BCA has awarded over $22 million in grants to support some of the most exciting and promising research by clinical doctors and research scientists across the country.

    About Breast Cancer Alliance
    BCA was founded in Greenwich, Connecticut by Mary Waterman after she was diagnosed with Stage IV breast cancer. Mary was determined to help others afflicted with breast cancer and with the support for her 5 friends, established Breast Cancer Alliance in 1996. While Mary succumbed to her cancer one year later, her courage and determination continue to inspire the Alliance’s growth. BCA sets itself apart from other charities by its strong connections to Greenwich and surrounding communities and the careful consideration to whom it distributes its supporters’ donations. Over its years, BCA has also maintained an active and loyal volunteer base and continues to expand its reach and support.

    You can learn more about Breast Cancer Alliance and its efforts to fight breast cancer by visiting its website or Facebook page.


    2015

    Dr. Mark Kris, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center

    ReMission Foundation supports Dr. Mark G. Kris, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, and his lung cancer research. Dr. Kris’ research efforts are focused on finding new genetic targets in cancer cells and testing anticancer medicines that specifically attack the lung cancers driven by these molecular changes. Through his research, Dr. Kris aims to discover better treatments for individuals with lung cancers by studying the genetic characteristics of their tumors. He works with surgeons and radiation specialists to find the best ways to use surgery, radiotherapy, and drugs together to increase the chance of cure.

    While many people still associate lung cancer with smokers, more than half of lung cancer diagnoses are in patients who never smoked or who already quit and the disease is actually the #2 leading cause of death in the U.S., second only to heart disease.

    About Mark G. Kris, MD
    Dr. Kris graduated from Cornell University Medical College and performed his residencies at The New York Hospital-Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He later received a fellowship from the Memorial Sloan Kettering Cancer Center where he has gone on to become the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is board certified in Internal Medicine and Medical Oncology and also leads Memorial Sloan Kettering’s project to train IBM’s Watson supercomputer to collect and interpret information about both the person and their cancer to help in selecting the best treatments.

    Dr. Kris currently is also leading a clinical trial — A Phase I Study of Certolizumab plus Chemotherapy for Patients with Stage IV Lung Adenocarcinoma — the goal of which is to identify a more effective treatment for lung cancer.


    2014

    Dr. Brett Miles, Head & Neck Cancer Research at the Icahn School of Medicine at Mount Sinai

    ReMission Foundation supports the efforts of the head and neck cancer program at the Icahn School of Medicine at Mount Sinai. Led by Dr. Brett Miles the program is working on fascinating procedures to improve the outcomes of patients being treated for head and neck cancer.

    Oral and oropharyngeal carcinomas are the sixth most common cancer in the world. Recent data indicates that the majority of tongue and tonsil cancers in the US will affect younger, non-smoking males. This is due to the Human Papilloma or HPV virus, which is spread through sexual contact.

    Through scientific discoveries in the laboratory and the use of image guided surgery including high-resolution microendoscopy the team is able to reduce the morbid effects of surgery providing for a more comfortable recovery and improved quality of life.

    As Director of Head and Neck Optical Imaging Research collaboration at Mount Sinai, Dr. Miles is currently evaluating novel imaging technology that would identify cancerous cells while the patient is still in surgery as opposed to afterwards where it is done in a laboratory. This technological advancement would allow for complete excision of all cancerous tissue while sparing as much normal tissue as possible.

    About Brett A. Miles, MD, DDS, FACS
    Dr. Miles is part of the Tisch Cancer Institute as a staff surgeon and oncologist. His research interests include novel optical imaging techniques, robotic surgery, reconstructive surgery and HPV related oropharyngeal cancer.


    2013

    Smiles4Shira

    ReMission Foundation supports Smiles4Shira in the fight against Hodgkin's Lymphoma.

    Smiles4Shira is a non-profit organization founded in 2010 when Shira Corbin Klein, loving wife and mother, was diagnosed with Hodgkin’s Lymphoma on New Year’s Eve. Both children and adults can develop Hodgkin lymphoma, but it is most common in early adulthood (especially in a person’s 20s). The American Cancer Society’s estimates that for this year, about 8,260 new cases (3,610 in females and 4,650 in males) and about 1,070 deaths (440 females, 630 males) from this cancer.

    For many afflicted with diseases like Shira’s, a stem cell transplant is required and they are unable to find a donor to help save their lives. You might be the one to help save a life.

    Smiles4Shira helps organize donor drives for Shira and find stem cell donor matches for all those afflicted with blood cancers. While no match has been found for Shira yet, through the organization's efforts 96 matches have been found to help save many lives. That's an incredible feat in such a short period of time and the more people that swab, the more people that live.

    You can find out more about Smiles4Shira on their Facebook page.


    2012

    Dr. Teena Bhatla and NYU’s Children’s Cancer Program in Hematologic Malignancies

    ReMission Foundation supports Dr. Teena Bhatla and NYU’s Children’s Cancer Program in Hematologic Malignancies in their continuing efforts to battle childhood cancers. Dr. Teena Bhatla is a faculty member in the Division of Pediatric Hematology-Oncology at NYU caring for children with hematologic malignancies in the inpatient unit and outpatient clinic. Dr. Bhatla completed her Residency Training at Maimonides Medical Center and recently finished her Clinical Fellowship at the NYU School of Medicine in the Pediatric Hematology-Oncology department, where she continues to pursue her promising research. Under the mentorship of Dr. Bill Carroll, Director of the NYU Cancer Institute, Dr. Bhatla and her colleagues in the Pediatric Leukemia Research Laboratory are studying the underlying biological pathways that mediate leukemia recurrences utilizing comprehensive genomic approaches to analyze the expression of genes and surrounding “epigenetic” structures during the evolution of acute lymphoblastic leukemia ALL from diagnosis to relapse.

    As part of her research efforts, Dr. Bhatla used Connectivity Map methodology to identify compounds that can potentially reverse the relapse signature in childhood ALL to restore sensitivity to chemotherapy. Dr. Bhatla and her colleagues have identified a signature of genes that are uniquely expressed at relapse and a clinical trial to target these genes has just opened within the Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium.

    Additionally, Dr. Bhatla is analyzing bone marrow and blood samples from children enrolled on the clinical trial described above to better understand how epigenetic drugs, such as Vorinostat, work to restore sensitivity to chemotherapy. This information offers promise for furthering the understanding of other childhood tumors as well.

    Visit the NYU Children’s Cancer Program in Hematologic Malignancies for more information.


    2011

    American Cancer Society

    For our inaugural year, ReMission Foundation supports the American Cancer Society (ACS). For nearly 100 years, the ACS has worked relentlessly to save lives and create a world with less cancer and more birthdays. Together with millions of our supporters worldwide, the ACS is helping people stay well, helping people get well, finding cures, and fighting back against cancer. Check out some of the great initiatives the ACS is sponsoring to help make a difference around the world by visiting their website.